During the EBEA Awards 2026 ceremony at the Athens Concert Hall, ELPEN won the Export Excellence Award in recognition of its consistently growing export activities. Today, the ELPEN Group is Greece’s largest pharmaceutical export company, employing 2,000 workers and operating two state-of-the-art manufacturing facilities in Pikermi and Keratea, Attica, while construction of another factory in the same region is underway.
Read: ELPEN: Awarded at 4th Reputation Pharma for promoting the company and Greek pharmaceuticals
ELPEN: Strong presence in EU and Middle East
ELPEN operates in more than 90 countries, with a strong presence in the European Union and the Middle East. Its exports account for 70% of total production. In 2025, ELPEN Group’s overseas sales exceeded those in the Greek market, with more than 80% of the company’s profitability coming from international activities. Meanwhile, exports in 2026 will exceed 300 million euros.
ELPEN’s international expansion is supported by the creation of overseas subsidiaries. ELPEN Pharma GmbH was established in Germany in 2012, followed by the founding of ELPEN Middle East Africa in Dubai in 2025.
Chief Operating Officer statements
Mr. Lefteris Tryfon, Chief Operating Officer of ELPEN Group, receiving the Export Excellence Award from Development Minister Takis Theodorikakos, stated: “On behalf of all of us at ELPEN, I would like to thank EBEA for this important distinction. This award comes in a milestone year for our company, as 2025 was the first time our overseas sales exceeded our sales in the Greek market.
Today, more than 10 million patients receive daily quality medicines produced here in Greece at our facilities. For me, this is the real message of today’s award and our journey in recent years: that Greece has strong scientific potential and companies that invest, innovate and can be competitive internationally”.
